2019, Number 6
<< Back Next >>
Med Crit 2019; 33 (6)
Toxic shock syndrome caused by Streptococcus in a hospital from the Mexico City
Díaz LIOA, Díaz CM
Language: Spanish
References: 14
Page: 334-339
PDF size: 258.63 Kb.
ABSTRACT
Streptococcal toxic shock syndrome was first described by Todd and collaborators in 1978, this syndrome includes hypotension, traces of cellular dysoxia, isolation
Streptococcus pyogenes; as well as two or more of the following criteria: acute respiratory distress syndrome, renal failure, liver abnormality, coagulopathy, skin rash with necrosis flaking of soft tissues. It is a relatively rare disease among children and adults, representing a high mortality ranging from 23 to 70%. In more than half of the cases the cause of entry of this pathogen into the bloodstream is unknown, although patients with alcoholism, on the edge of death, with splenectomy, with comorbidities (chronic kidney disease, liver failure, leukemia) are more susceptible to infection, to acquire severe infections and shock. Cutaneous infections usually are followed by minor skin irritations (insect bites), 20% of the cases experience a flu-like syndrome (fever, chills, myalgia and diarrhea). In patients who develop deep soft tissue infections such as necrotizing fasciitis or intrauterine infection, the severe pain is the most common initial symptom of streptococcal TSS.
REFERENCES
Wood TF, Potter MA, Jonasson O. Streptococcal toxic shock-like syndrome. The importance of surgical intervention. Ann Surg. 1993;217(2):109-114. doi: 10.1097/00000658-199302000-00003.
Stevens DL. Streptococcal toxic-shock syndrome: spectrum of disease, pathogenesis, and new concepts in treatment. Emerg Infect Dis. 1995;1(3):69-78.
Fox KL, Born MW, Cohen MA. Fulminant infection and toxic shock syndrome caused by Streptococcus pyogenes. J Emerg Med. 2002;22(4):357-366.
Patterson MJ. Streptococcus. In: Baron S, editor. Medical microbiology. 4th edition. Galveston (TX): University of Texas Medical Branch at Galveston; 1996. Chapter 13. Available from: https://www.ncbi.nlm.nih.gov/books/NBK7611/
Schmitz M, Roux X, Huttner B, Pugin J. Streptococcal toxic shock syndrome in the intensive care unit. Ann Intensive Care. 2018;8(1):88.
Stevens DL. Streptococcal toxic shock syndrome associated with necrotizing fasciitis. Annu Rev Med. 2000;51:271-288.
Baxter M, Morgan M. Streptococcal toxic shock syndrome caused by group g streptococcus, United Kingdom. Emerg Infect Dis. 2017;23(1):127-129.
Mizuguchi Y, Taniguchi N, Takahashi A. Successful treatment of out-of-hospital cardiopulmonary arrest due to streptococcal toxic shock syndrome - effectiveness of extracorporeal membrane oxygenation and the rapid antigen group A streptococcus test: a case report. J Med Case Rep. 2018;12(1):244.
Reich HL, Crawford GH, Pelle MT, James WD. Group B streptococcal toxic shock-like syndrome. Arch Dermatol. 2004;140(2):163-166.
Wilkins AL, Steer AC, Smeesters PR, Curtis N. Toxic shock syndrome - the seven Rs of management and treatment. J Infect. 2017;74 Suppl 1:S147-S152.
Lamagni TL, Efstratiou A, Vuopio-Varkila J, Jasir A, Schalén C; Strep-EURO. The epidemiology of severe Streptococcus pyogenes associated disease in Europe. Euro Surveill. 2005;10(9):179-184.
Centers for Disease Control and Prevention (CDC). Invasive group A streptococcal infections--United Kingdom, 1994. MMWR Morb Mortal Wkly Rep. 1994;43(21):401-402.
Shah PJ, Vakil N, Kabakov A. Role of intravenous immune globulin in streptococcal toxic shock syndrome and Clostridium difficile infection. Am J Health Syst Pharm. 2015;72(12):1013-1019.
Georgouras KE, Konya J, Pang B. Toxic streptococcal syndrome. In: Stanford DG. The Dertmatology Centre. Sydney, New South Wales, Australia: Liverpool Hospital; 1997.